Literature DB >> 27353327

Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.

Jaine K Blayney1, Timothy Davison2, Nuala McCabe2, Steven Walker2, Karen Keating3, Thomas Delaney3, Caroline Greenan2, Alistair R Williams4, W Glenn McCluggage5, Amanda Capes-Davis6, D Paul Harkin2, Charlie Gourley7, Richard D Kennedy2.   

Abstract

Here, we describe gene expression compositional assignment (GECA), a powerful, yet simple method based on compositional statistics that can validate the transfer of prior knowledge, such as gene lists, into independent data sets, platforms and technologies. Transcriptional profiling has been used to derive gene lists that stratify patients into prognostic molecular subgroups and assess biomarker performance in the pre-clinical setting. Archived public data sets are an invaluable resource for subsequent in silico validation, though their use can lead to data integration issues. We show that GECA can be used without the need for normalising expression levels between data sets and can outperform rank-based correlation methods. To validate GECA, we demonstrate its success in the cross-platform transfer of gene lists in different domains including: bladder cancer staging, tumour site of origin and mislabelled cell lines. We also show its effectiveness in transferring an epithelial ovarian cancer prognostic gene signature across technologies, from a microarray to a next-generation sequencing setting. In a final case study, we predict the tumour site of origin and histopathology of epithelial ovarian cancer cell lines. In particular, we identify and validate the commonly-used cell line OVCAR-5 as non-ovarian, being gastrointestinal in origin. GECA is available as an open-source R package.
© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Year:  2016        PMID: 27353327      PMCID: PMC5041471          DOI: 10.1093/nar/gkw578

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  39 in total

1.  First searchable database for DNA profiles of human cell lines: sequential use of fingerprint techniques for authentication.

Authors:  W Dirks; R A MacLeod; K Jäger; H Milch; H G Drexler
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1999-09       Impact factor: 1.770

Review 2.  Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.

Authors:  John Hornberger; Michael D Alvarado; Chien Rebecca; Hialy R Gutierrez; Tiffany M Yu; William J Gradishar
Journal:  J Natl Cancer Inst       Date:  2012-07-05       Impact factor: 13.506

3.  Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties.

Authors:  James M Rae; Susan J Ramus; Mark Waltham; Jane E Armes; Ian G Campbell; Robert Clarke; Robert J Barndt; Michael D Johnson; Erik W Thompson
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers.

Authors:  Garrett M Dancik; Yuanbin Ru; Charles R Owens; Dan Theodorescu
Journal:  Cancer Res       Date:  2011-10-19       Impact factor: 12.701

5.  Bring on the biomarkers.

Authors:  George Poste
Journal:  Nature       Date:  2011-01-13       Impact factor: 49.962

6.  MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research.

Authors:  James M Rae; Chad J Creighton; Jeanne M Meck; Bassem R Haddad; Michael D Johnson
Journal:  Breast Cancer Res Treat       Date:  2006-09-27       Impact factor: 4.872

7.  Molecular classification of human carcinomas by use of gene expression signatures.

Authors:  A I Su; J B Welsh; L M Sapinoso; S G Kern; P Dimitrov; H Lapp; P G Schultz; S M Powell; C A Moskaluk; H F Frierson; G M Hampton
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

8.  Colorectal cancer cell lines lack the molecular heterogeneity of clinical colorectal tumors.

Authors:  James Todd Auman; Howard L McLeod
Journal:  Clin Colorectal Cancer       Date:  2010-01       Impact factor: 4.481

9.  Type-specific cell line models for type-specific ovarian cancer research.

Authors:  Michael S Anglesio; Kimberly C Wiegand; Nataliya Melnyk; Christine Chow; Clara Salamanca; Leah M Prentice; Janine Senz; Winnie Yang; Monique A Spillman; Dawn R Cochrane; Karey Shumansky; Sohrab P Shah; Steve E Kalloger; David G Huntsman
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

10.  Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens.

Authors:  Torsten Nielsen; Brett Wallden; Carl Schaper; Sean Ferree; Shuzhen Liu; Dongxia Gao; Garrett Barry; Naeem Dowidar; Malini Maysuria; James Storhoff
Journal:  BMC Cancer       Date:  2014-03-13       Impact factor: 4.430

View more
  10 in total

1.  DNA barcoded competitive clone-initiating cell analysis reveals novel features of metastatic growth in a cancer xenograft model.

Authors:  Syed Mohammed Musheer Aalam; Xiaojia Tang; Jianning Song; Upasana Ray; Stephen J Russell; S John Weroha; Jamie Bakkum-Gamez; Viji Shridhar; Mark E Sherman; Connie J Eaves; David J H F Knapp; Krishna R Kalari; Nagarajan Kannan
Journal:  NAR Cancer       Date:  2022-07-22

2.  Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations.

Authors:  Mitchell Acland; Noor A Lokman; Clifford Young; Dovile Anderson; Mark Condina; Chris Desire; Tannith M Noye; Wanqi Wang; Carmela Ricciardelli; Darren J Creek; Martin K Oehler; Peter Hoffmann; Manuela Klingler-Hoffmann
Journal:  Cancers (Basel)       Date:  2022-06-02       Impact factor: 6.575

3.  Multiple Components of Protein Homeostasis Pathway Can Be Targeted to Produce Drug Synergies with VCP Inhibitors in Ovarian Cancer.

Authors:  Prabhakar Bastola; Gary S Leiserowitz; Jeremy Chien
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

4.  Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.

Authors:  Yao-An Shen; Jiaxin Hong; Ryoichi Asaka; Shiho Asaka; Fang-Chi Hsu; Yohan Suryo Rahmanto; Jin-Gyoung Jung; Yu-Wei Chen; Ting-Tai Yen; Alicja Tomaszewski; Cissy Zhang; Nabeel Attarwala; Angelo M DeMarzo; Ben Davidson; Chi-Mu Chuang; Xi Chen; Stephanie Gaillard; Anne Le; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2020-08-28       Impact factor: 12.701

5.  Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.

Authors:  Brandt C Huddle; Edward Grimley; Cameron D Buchman; Mikhail Chtcherbinine; Bikash Debnath; Pooja Mehta; Kun Yang; Cynthia A Morgan; Siwei Li; Jeremy Felton; Duxin Sun; Geeta Mehta; Nouri Neamati; Ronald J Buckanovich; Thomas D Hurley; Scott D Larsen
Journal:  J Med Chem       Date:  2018-09-28       Impact factor: 7.446

6.  A novel role for NUAK1 in promoting ovarian cancer metastasis through regulation of fibronectin production in spheroids.

Authors:  Jamie Lee Fritz; Olga Collins; Parima Saxena; Adrian Buensuceso; Yudith Ramos Valdes; Kyle E Francis; Kevin R Brown; Brett Larsen; Karen Colwill; Anne-Claude Gingras; Robert Rottapel; Trevor G Shepherd
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

7.  PAUF as a Target for Treatment of High PAUF-Expressing Ovarian Cancer.

Authors:  Yeon Jeong Kim; Fen Jiang; Jin Park; Hyeon Hee Jeong; Ji Eun Baek; Seung-Mo Hong; Seong-Yun Jeong; Sang Seok Koh
Journal:  Front Pharmacol       Date:  2022-05-06       Impact factor: 5.810

8.  The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer.

Authors:  Monal Patel; Yinu Wang; Elizabeth T Bartom; Rohin Dhir; Kenneth P Nephew; Daniela Matei; Andrea E Murmann; Ernst Lengyel; Marcus E Peter
Journal:  Cancer Res       Date:  2021-06-15       Impact factor: 12.701

Review 9.  The Endometriotic Tumor Microenvironment in Ovarian Cancer.

Authors:  Jillian R Hufgard Wendel; Xiyin Wang; Shannon M Hawkins
Journal:  Cancers (Basel)       Date:  2018-08-07       Impact factor: 6.639

10.  Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.

Authors:  Marine Bruand; David Barras; Marco Mina; Eleonora Ghisoni; Matteo Morotti; Evripidis Lanitis; Noémie Fahr; Mathieu Desbuisson; Alizée Grimm; Hualing Zhang; Chloe Chong; Julien Dagher; Sora Chee; Theodora Tsianou; Julien Dorier; Brian J Stevenson; Christian Iseli; Catherine Ronet; Sara Bobisse; Raphael Genolet; Josephine Walton; Michal Bassani-Sternberg; Lana E Kandalaft; Bing Ren; Iain McNeish; Elizabeth Swisher; Alexandre Harari; Mauro Delorenzi; Giovanni Ciriello; Melita Irving; Sylvie Rusakiewicz; Periklis G Foukas; Fabio Martinon; Denarda Dangaj Laniti; George Coukos
Journal:  Cell Rep       Date:  2021-07-20       Impact factor: 9.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.